Brief: Karyopharm Therapeutics Q1 product revenue USD 28.288 million
04/05/2023 12:53
May 4 (Reuters) - Karyopharm Therapeutics Q1 operating income USD -30.899 million. * Q1 operating expenses USD 69.597 million * Q1 product revenue USD 28.288 million * Q1 net income USD -34.126 million * Outlook FY revenue USD 145-160 million
Recent news on Karyopharm Therapeutics
See all newsBrief: Karyopharm Therapeutics - Enters Forbearance Agreement And Waiver On Sept 10, 2026 - SEC Filing
Brief: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Karyopharm Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Karyopharm Q2 revenue falls as license revenue drops; expects funds to last into September
Karyopharm Therapeutics Inc. expected to post a loss of $1.28 a share - Earnings Preview